Agrylin and Depression - a phase IV clinical study of FDA data

Summary:

Depression is reported as a side effect among people who take Agrylin (anagrelide hydrochloride), especially for people who are female, 60+ old, also take Jakafi, and have Essential thrombocythaemia.

The phase IV clinical study analyzes which people have Depression when taking Agrylin. It is created by eHealthMe based on reports of 1,248 people who have side effects when taking Agrylin from the FDA, and is updated regularly.

What is Agrylin?

Agrylin has active ingredients of anagrelide hydrochloride. It is often used in primary thrombocythemia. eHealthMe is studying from 1,256 Agrylin users. Check the latest studies of Agrylin.

What is Depression?

Depression is found to be associated with 3,167 drugs and 4,125 conditions by eHealthMe. Check the latest studies of Depression.

On Jul, 15, 2026

1,248 people reported to have side effects when taking Agrylin.
Among them, 20 people (1.6%) have Depression.

Among these 20 people:

What is the gender of people who have Depression when taking Agrylin? *

female: 92.31 %
male: 7.69 %

What is the age of people who have Depression when taking Agrylin? *

What are other drugs people take besides Agrylin? *

What are other side effects people have besides Depression? *

Anaemia (lack of blood): 10 people, 50.00%
Headache (pain in head): 10 people, 50.00%
Fever: 7 people, 35.00%
Herpes Zoster: 6 people, 30.00%
Stress And Anxiety: 6 people, 30.00%
Insomnia (sleeplessness): 4 people, 20.00%
Diarrhea: 4 people, 20.00%
Dizziness: 4 people, 20.00%
Gastroenteritis Viral (inflammation of stomach and intestine caused by virus infection): 3 people, 15.00%
Limb Discomfort (discomfort in leg): 3 people, 15.00%

What are the existing conditions these people have? *

Essential Thrombocythaemia (chronic blood cancer): 6 people, 30.00%
Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 3 people, 15.00%
Restless Leg Syndrome (a powerful urge to move your legs): 2 people, 10.00%
Migraine (headache): 2 people, 10.00%
High Blood Cholesterol: 2 people, 10.00%
Primary Myelofibrosis (primary disorder of the bone marrow): 1 person, 5.00%
Platelet Count Increased: 1 person, 5.00%
Pain: 1 person, 5.00%
Neuralgia (pain in one or more nerves): 1 person, 5.00%
Nausea (feeling of having an urge to vomit): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Agrylin and have Depression?

- Check whether Depression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Agrylin:

Agrylin (1,256 reports)

Depression treatments and more:

Depression (652,144 reports)

Browse all side effects of Agrylin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Depression:

Depression (3,167 drugs)

Browse all the conditions that are associated with Depression:

Depression (4,125 conditions)

Related publications that referenced our studies

Pang, T., & Gudi, A., "Chest pain following the use of fluvoxamine in depression", Proceedings of Singapore Healthcare, 2018 Jan .
Pang, T., & Gudi, A., "Chest pain following the use of fluvoxamine in depression", Proceedings of Singapore Healthcare, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on anagrelide hydrochloride (the active ingredients of Agrylin) and Agrylin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.